| Dr Gerald E Weitz, DDS | |
|
1410 S Main St, Moscow, ID 83843-8930 | |
| (208) 882-3214 | |
| (208) 882-2605 |
| Full Name | Dr Gerald E Weitz |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 1410 S Main St, Moscow, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437278090 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | D1546 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gerald E Weitz, DDS 1410 S Main St, Moscow, ID 83843-8930 Ph: (208) 882-3214 | Dr Gerald E Weitz, DDS 1410 S Main St, Moscow, ID 83843-8930 Ph: (208) 882-3214 |
News Archive
A shift in the life science market has begun to steer cell culture scientists to re-evaluate their use of native transferrin and iron chelators to pursue recombinant alternatives. Transferrin regulates the uptake, transport and utilization of iron for cellular function, increasing cell growth and productivity. Native transferrin found in bovine or human serum has been widely used in cell culture for these added benefits. However, regulatory issues continue to arise with the use of native transferrin due to blood-borne pathogens.
Even when health care experiences go well, patients and their families can still suffer harm. To date, organizational efforts to reduce harm have focused primarily on physical harm, but other forms of harm are both prevalent and equally as important.
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin (bevacizumab - Genentech/Roche) in a preclinical model of breast cancer.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
› Verified 2 days ago
Dr. Karen Marie Sept, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 1246 W A St, Moscow, ID 83843 Phone: 208-882-9999 Fax: 208-882-9998 | |
Richard E. Bailey, D.M.D. Dentist Medicare: Not Enrolled in Medicare Practice Location: 301 Quail Run Dr, Moscow, ID 83843 Phone: 509-336-8478 | |
Dr. John Andrew Werner, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 619 S Washington St Ste 303, Moscow, ID 83843 Phone: 208-883-7777 | |
Dr. John Wallace Morrison, D.M.D. Dentist Medicare: Not Enrolled in Medicare Practice Location: 2301 W A St, Suite A, Moscow, ID 83843 Phone: 208-882-0331 Fax: 208-882-1579 | |
Dr. Wayne Michael Peterson, DMD Dentist Medicare: Medicare Enrolled Practice Location: 1138 W A St, Moscow, ID 83843 Phone: 208-882-9310 Fax: 208-882-8601 | |
Dr. James Wilmer Garrett, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 1215 E 6th St, Moscow, ID 83843 Phone: 208-882-9585 Fax: 208-883-8859 | |
Richard Lee George, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1046 Wallen Rd, Moscow, ID 83843 Phone: 208-882-4990 Fax: 208-882-4990 |